Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in ve...
1750 Elm Street
Manchester, NH 03104
Founded in 2009
Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015
Apr 6 15
Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 . Venue: Caesars Palace, Las Vegas, Nevada, United States.
Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014
Mar 27 15
Boston Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and fiscal year ended December 31, 2014. For the quarter, the company reported revenue of $12,871 compared to revenue of $80,438 for the fourth quarter ended December 31, 2013. Net loss was $762,495 or $0.02 per basic and diluted share, compared with a net loss of $2,297,972 or $0.06 per basic and diluted share in the prior year's fourth quarter. Operating loss was $756,854 compared to $2,293,123 a year ago.
For the year, the company reported revenue of $199,582 compared to revenue of $323,412 for fiscal 2013. The decrease for fiscal 2014 is primarily due to decreased shipments of SUGARDOWN to the company's one significant customer, APC. Net loss was $4,699,939 or $0.12 per basic and diluted share, compared with a net loss of $4,601,503 or $0.18 per basic and diluted share for fiscal 2014. Operating loss was $4,674,347 compared to $4,580,245 a year ago.
Boston Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Mar 27 15
Boston Therapeutics, Inc. filed its 10-K on Mar 27, 2015 for the period ending Dec 31, 2014. In this report its auditor, McGladrey LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.